Navigation Links
Data Demonstrate that Obagi Medical Products' Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures

Study of more than 2,500 patients shows marked improvement of skin texture,

color and overall appearance

SAN ANTONIO, Feb. 1 /PRNewswire-FirstCall/ -- Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced the results of a wide-ranging investigator assessment study on the effects of its Condition & Enhance System on facial rejuvenation procedures today at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio. The data show that the unique 4% hydroquinone- based system in combination with common non-surgical and surgical facial rejuvenation procedures improved overall skin quality in up to 80 percent of subjects.

As rated by investigators, eighty-three percent of patients treated with the Condition & Enhance System and botulinum toxin type A injections (i.e., Botox(R)) experienced a 1-grade improvement (from moderate to mild or mild to none) in hyperpigmentation. Additionally, 33 percent of subjects achieved a 2-grade improvement (from severe to mild or moderate to none) in this type of sun damage related discoloration. Similar levels of improvement were also seen in tactile roughness and sallowness. These results are independent of the effects of botulinum toxin type A, therefore supporting the benefit of using the unique Condition & Enhance System in order to provide a more balanced overall aesthetic result.

The 4% hydroquinone-based skin care program, known commercially as the Obagi(R) Condition & Enhance System, helps correct premature photoaged skin and prevent future skin damage. The system is comprised of products that work together to improve overall skin health and appearance. The Condition & Enhance System, utilizing Obagi's Penetrating Therapeutics(TM), includes cleanser, toner, 4% hydroquinone, exfoliant, and sunscreen SPF 35 for complete skin care.

"Using the Condition & Enhance System, with 4% hydroquinone, improves overall skin quality and is an effective adjunct to both non-surgical and surgical facial rejuvenation procedures," said Jody Comstock, MD, Skin Spectrum, Tucson, AZ, and lead investigator. "With continued advances in technology, the number of cosmetic dermatology procedures is on the rise and it is important to have a safe, effective skin care regimen to complement these procedures and address total skin rejuvenation and the maintenance of skin improvement."

Other results of the study include:

-- Investigators gave ratings of "good" or "excellent" improvement in

overall skin quality in at least 80 percent of patients treated with

the Obagi(R) Condition & Enhance System as pre and post-conditioning

in combination with:

-- Botulinum toxin type A

-- Intense pulsed light therapy

-- Non-ablative laser therapy

-- Ablative chemical peel

-- Surgery

-- Investigators gave ratings of "good" or "excellent" improvement in

overall skin quality in at least 70% of patients treated with the

Obagi(R) Condition & Enhance System as pre and post-conditioning in

combination with:

-- Non-ablative chemical peel

-- Microdermabrasion

-- Ablative laser therapy

-- Laser resurfacing

Of the more than 2,500 patients assessed in the study, 52 percent had non- ablative/non-surgical procedures such as botulinum toxin type A injections, intense pulsed light therapy, and filler injections, while 46 percent had ablative/surgical procedures such as laser therapy, chemical peels, and surgery. Patients used the Condition & Enhance System in conjunction with their facial rejuvenation procedure to enhance their overall aesthetic result. Mean duration of use of the Condition & Enhance System in this study was 4 weeks pre-conditioning and 6 weeks post-conditioning.

The order and frequency of application of Condition & Enhance are carefully defined and managed by the physician to create a 4-step process for improving and restoring overall skin quality. The first step is skin preparation, the second step is skin correction, the third step is skin stimulation, and the fourth step is skin protection.

"The results of this large-scale study reinforce the efficacy and tolerability of Condition & Enhance, and we are pleased to provide a system that works in concert with some of today's most sought-after facial rejuvenation procedures to help improve clinical outcomes," said Steve Carlson, President & CEO, Obagi Medical Products, Inc.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm, 1988; Obagi-C Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi Professional-C (a line of highly stable vitamin C serums), 2005; Obagi Nu-Derm Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm eye treatment and Obagi CLENZIderm M.D. acne therapeutic systems, 2007; and a formulation of CLENZIderm for normal to dry skin, June 2007. Obagi's products are only available through physicians. Visit for information.

Botox(R) is a registered trademark of Allergan, Inc.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2006. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.

SOURCE Obagi Medical Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
7. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
8. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve ... the bather’s style and personality. From basic styles for the purist looking for ...
(Date:11/25/2015)... , ... November 26, 2015 , ... ... Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public ... in Nairobi (UNON) for the opening of the 5th African Network for Drugs ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
Breaking Medicine News(10 mins):